Human peripheral blood neutrophils (PMN) plated onto fibrinogen and activated with FMLP release HtOt and lactoferrin, a specific granule component, with parallel kinetics. Although tumor necrosis factor-a (TNFa) only primes PMN in suspension, it is a potent agonist of adherent PMN. Activation of adherent PMN by FMLP (lo-' mol/L) stimulated detectable release of TNFa within 45 minutes of stimulation, with maximal release (45.5 pg/106 cells) detected by 90 minutes. TNFa release paralleled the release of both lactoferrin and HZ02. To determine if TNFa plays a role in H202 and lactoferrin release, we investigated the effect of anti-TNFa antibodies on FMLP-stimulated activation of adherent PMN. A neutralizing rabbit anti-TNFa antibody inhibited both HZ02 and lactoferrin release stimulated by FMLP, whereas rabbit IgG, anti-HLA-A.B.C. anti-CD14, and anti-interleukin-8 antibodies were without effect. The simultaneous addition of TNFa (1.000 U/mL) with anti-TNFa antibody reversed the inhibition seen with anti-TNFa alone. Furthermore, treat-UMOR NECROSIS FACTOR-a (TNFa) is a potent T cytokine that has diverse effects on tissues in vivo and in vitro.'.* Upon activation, TNFa is synthesized and released by leukocytes including PMN.'.4 It has been shown, for example, that treating peripheral blood neutrophils (PMN) with lipopolysaccharide, granulocyte-macrophage colony-stimulating factor (GM-CSF), or interleukin-2 (IL-2) induces the appearance of TNFa mRNA within 30 minutes,' with TNFa being released by 60
T cytokine that has diverse effects on tissues in vivo and in vitro.'.* Upon activation, TNFa is synthesized and released by leukocytes including PMN.'.4 It has been shown, for example, that treating peripheral blood neutrophils (PMN) with lipopolysaccharide, granulocyte-macrophage colony-stimulating factor (GM-CSF), or interleukin-2 (IL-2) induces the appearance of TNFa mRNA within 30 minutes,' with TNFa being released by 60 In addition to de novo synthesis, TNFa has been localized to at least two different cellular compartments in resting and activated cells. In resting cells, TNFa is found in intracellular compartments, such as the large secretory granules of mast cells* and the secretory granules of Paneth cells.' After endotoxin treatment in vivo, TNFa has been observed on the plasma membrane and in the secretory granules of eosinophils, neutrophils, and monocytes from bone marrow, spleen, lung, and the proximal intestine.'.'" In addition, metalloproteinases can release a bioactive TNFa from the membrane-bound, 26-kD form." Thus, TNFa from activated PMN may come from de novo synthesis or can be released from secretory granules or the plasma membrane.
Two receptors for TNFa have been described and cloned having relative molecular weights of 55 and 7.5 kD (p5.5 and p7.5, respectively). Both of these receptors are constitutively expressed on PMN" I s and the promyelocytic leukemia cell line, HL-60.I6 Recently, Richter et a1" showed that both p55 and p75 are required for superoxide production by adherent PMN stimulated with TNFa. However, the nature of the relationship between these two receptors was not examined. Both p55 and p75 are also required for TNFa potentiation of Fc-mediated phagocytosis. In this case, p55 is required for signaling, whereas p75 regulates the binding of TNFa
The mechanisms by which TNFa activates PMN remain unclear. However, in HL-60 and other cells, ligation of TNFa receptors leads to rapid and transient increases in both diacylglycerol and ceramide.'* These second messengers are increased when PMN are activated by phorbol 12-myristate 13-acetate or FMLP,'"'" and ceramide levels also increase after activation by TNFa." For PMN activated while in suspension, TNFa increases FMLP-mediated phospholipase D activation, suggesting that there may be cross-talk between these two signaling pathways.** Thus, it is possible that ligation of TNFa receptors initiates a signaling cascade that influences FMLP-mediated phospholipase D (PLD) activation in adherent PMN as well."
In addition to cross-talk between signaling pathways, there are recent studies that show a physical association between two different surface receptors. For example, resonance energy transfer was used to show that CR3 links FcRIII receptors to the cytoskeleton, supporting more indirect evidence that these receptors function together during PMN activation. 24 In another s t~d y , '~ it was shown that an 
MATERIALS AND METHODS

Reagents.
Monoclonal rat antihuman p75 and mouse antihuman p55 antibodies were obtained from Genzyme (Cambridge, MA) and used at a final concentration of 20 mg/mL. Monoclonal anti-CD14 antibody was obtained from AMAC, Inc (Westbrook, ME) and used at a final concentration of 10 mg/mL. Horse antithymic HLA-A,B,C antisera was generously provided by Dr James Baker (University of Michigan, Ann Arbor, MI) and used at a final concentration of 0.18 mg/mL. Fibrinogen was obtained from Kabi Diagnostics (Franklin, OH). Human and murine TNFa were obtained from Genentech (South San Francisco, CA). TNFa antisera was prepared by immunizing rabbits with recombinant human TNFa (Cetus Corp, Emmeryville, CA), as previously described.32 Anti-TNFa antisera and normal rabbit IgG were used at final concentrations of 1:20 dilution (1.5 mg/mL and 1 mg/mL, respectively, final concentration). All other reagents were obtained from the Sigma Chemical Co (St Louis, MO), unless stated otherwise.
Human peripheral blood PMN were isolated from whole blood using dextran sedimentation, FicolVHypaque centrifugation, and hypotonic lysis of residual erythrocytes exactly as described.'' Preparations were greater than 95% PMN by differential staining and were greater than 98% viable by trypan blue exclusion. Nonspecific esterase measurements indicate less than 1 % contamination by monocytes.
HzOz released by adherent PMN was assayed as previously de~cribed.~' Assays were conducted in 24-well, flat-bottomed polystyrene Falcon Primaria tissue culture plates (Becton Dickinson, Lincoln Park, NJ) coated with saturating concentrations of fibrinogen (50 pg/mL). PMNs suspended in Krebs-Ringer phosphate buffer containing glucose (KRPG) were added to fibrinogencoated wells ( 1 X 10' cells/well) containing KRPG and 24 mmoVL scopoletin, 5 pg of horseradish peroxidase, 1 mmovL sodium azide (to prevent destruction of H202 by myeloperoxidase and catalase), and the indicated agonists and/or inhibitors in a final volume of 1 mL. Before their addition to the plate, PMN were warmed to 22°C and plates were prewarmed to 37°C. Plates containing PMN were incubated in humidified air at 37°C. At the indicated time intervals, Cells.
HzO, assay.
the solution in the wells was centrifuged to remove unattached cells and the supernatant was transferred to cuvettes. The reduction in relative fluorescence due to the oxidation of scopoletin by HZO2 was measured using an excitation wavelength of 365 nm and an emission wavelength of 473 nm in a Perkin-Elmer LS-SOB fluorescence spectrometer (Perkin-Elmer, Norwalk, CT). The loss of scopoletin fluorescence was specific for HZO2 because omission of horseradish peroxidase abolished the response. In control samples, KRPG plus vehicle was substituted for agonists and inhibitors. A standard curve was generated using known concentrations of Hz02.
Enzyme-linked immunosorbent assay (ELISA) for lactoferrin and TNFa. Samples that were evaluated for HZ02 release were also examined for lactofemn. Lactofemn release was determined using the highly sensitive ELISA described by B i r g e n~.~~ The lactoferrin concentration in samples was calculated using a standard curve. The release of TNFa from PMN was quantitated using the Quantikine HS ELISA kit (R&D Systems, Minneapolis, MN). TNFa levels were calculated using a standard curve as outlined by the manufacturer.
Data were presented as the mean values t SEM. Data were analyzed by paired, two-tailed Student's t-test using the Instat Graph-Pad computer program (Graph Pad, San Diego, CA).
Statistical analysis.
RESULTS
TNFa stimulates the release of H202 from adherent PMN. 34 We confirmed that recombinant human and murine TNFa stimulated H202 release by PMN plated onto fibrinogen. H202 release stimulated by TNFa was apparent by 30 minutes ( P < .05 v control) and reached maximal levels by 60 minutes (Fig 1) (Fig 1) . Because the lag period was shorter for TNFa-stimulated cells than for FMLP-stimulated cells (30 v 45 minutes) and because ligation of P2-integrins is known to influence TNFa production,28 we speculated that TNFa might be synthesized and released after stimulation with FMLP. We found that PMN plated onto fibrinogen and stimulated with FMLP mol/ L) released significant ( P < .05) amounts of TNFa by 45 minutes (Fig 2) , reaching maximal levels by 90 minutes. In contrast, control cells at time = 0 or incubated in wells containing fibrinogen for as long as 60 minutes did not release detectable levels of TNFa (Fig 2) .
To determine whether the release of TNFa was contributing to PMN activation in our assay system, we evaluated the effect of anti-TNFa antibodies on H202 and lactoferrin release by PMN plated onto fibrinogen and activated with FMLP. Consistent with a role for TNFa in FMLP-mediated activation, rabbit anti-TNFa inhibited both H202 and lactofenin release (Fig 3) . The simultaneous addition of recombinant human TNFa (1,000 U/mL) with anti-TNFa overcame the inhibition (Fig 4, m) , indicating that the antibody effect was specific for TNFa. In contrast, control IgG and antibodies specific for HLA-A,B,C, IL-8, and CD14 has no effect on H202 release (Fig 4) . It should be noted that anti-TNFa antibodies were effective at inhibiting H202 release only if added within 45 minutes of FMLP addition (Fig 5) .
To confirm our studies with anti-TNFa antibody and determine which TNFa receptor was mediating this response, we tested the effect of anti-p55 and anti-p75 antibodies on FMLP-mediated H202 release by adherent PMN. The addition of either anti-p55 or anti-p75 alone to our assay system resulted in a small but significant ( P < .01) reduction in H202 release by 120 minutes (Table 1) . However, the combination of both antibodies reduced H202 release to control levels. Neither murine nor rat IgG inhibited H202 release (data not shown). The combination of anti-p55 and antip75 antibodies had no effect on H202 release stimulated by phorbol 12-myristate 13-acetate (PMA; Table l), which activates PMN by bypassing the membrane and directly activating protein kinase C. The TNFa released during FMLP-induced PMN activation could come from three potential sources. First, it could come from a pre-existing intracellular pool because intracellular stores of TNFa have been reported in unstimulated PMN.8.9.'5 Second, TNFa bound to the plasma membrane could be released by proteolysis." Finally, TNFa could be derived through de novo synthesis. To determine if the TNFa affecting FMLP-stimulated activation of adherent PMN is newly synthesized, we treated cells with 10 mol& actinomycin D or cycloheximide before conducting our assays. Under these conditions, either agent reduced H202 and lactoferrin release to control levels (Fig 6) , ie, values from treated cells were not statistically different from control values. The addition of TNFa to PMN treated with either actinomycin D or cycloheximide returned H202 and lactoferrin levels to those seen with FMLP stimulation (data not shown). These data indicate that the TNFa released during activation of FMLP- stimulated PMN is newly synthesized and is most likely involved in the activation cascade.
DISCUSSION
Some agonists, such as GM-CSF and TNFa, do not stimulate functional responses by PMN in suspension, but prime them for a heightened response to a subsequent stimuOn the other hand, the same stimuli activate PMN adherent to extracellular matrix protein^.^".'^.'^-.'' Nathan29
showed that TNFa stimulates adherent PMN to release H202. We confirmed and extended these findings by showing that TNFa activated adherent PMN to release both H202 and lactoferrin with kinetics similar to those of FMLP, but found that TNFa activated PMN with a shorter lag period than FMLP. TNFa, released in nanogram quantities from endothelium and monocytes during inflammation, acts as an agonist for other cells in vivo and in vitro. In addition, TNFa has been implicated as an autocrine factor in HL-60 cells, lymphocytes, and macrophage?*4 when cells are stimulated with an agonist other than TNFa. We found that the release of TNFa by FMLP-activated PMN correlated with the release of both HzOz and lactofemn. Other reports have documented that TNFa mRNA is produced by PMN within 30 to 60 minutes after stimulation with LPS or IL-2?.'.' Thus, it is plausible that the TNFa released by PMN stimulated with FMLP and adherent to fibrinogen serves as a secondary stimulus to activate H 2 0 2 and lactoferrin release. However, these results do not preclude the possibility that TNFa may be 1~~.22.26..'6.37 playing a role other than that of an autocrine factor. We showed that anti-TNFa antibodies significantly inhibited, but did not completely block, the release of both Hz02 and lactoferrin from FMLP-stimulated PMN adherent to fibrinogen. These results suggest that additional signal transduction pathways leading to oxidant and lactofemn release are activated by FMLP. We showed that blocking TNFa and TNFa receptors with antibodies and blocking protein synthesis inhibited H202 and lactoferrin release stimulated by FMLP. These data support our hypothesis that TNFa release and ligation of TNFa receptors are important for FMLP-stimulated oxidant release from adherent PMN.
The cellular source of the TNFa released from PMN was not defined in the present report. Three possibilities exist for Finally, TNFa may be transcribed andor translated after PMN stimulation, as suggested by the data in Fig 6. We found that either actinomycin D or cycloheximide inhibited both HzOz and lactofenin release and that the addition of TNFa reversed the inhibition, suggesting that PMN synthesize TNFa after FMLP stimulation. Beil et a14' localized TNFa to the Golgi complex of PMN from colonic biopsies of patients with Crohn's disease, suggesting that TNFa is synthesized by PMN during inflammation. In addition to translation, others have shown that PMN increase transcription by 30 minutes after stimulation with FMLP, GM-CSF, or TNFI~!~ Although it is clear that exogenous TNFa stimulates adherent PMN, the roles that each of the TNFa receptors play in functional activation are not well established. It is known that PMN express both p55 and p75 TNFa receptor^"^'^.^ and our data show that both receptors play a role in FMLP activation of PMN adherent to fibrinogen. Specifically, we found that anti-p55 and anti-p75 each moderately inhibited oxidant release, but the combination of both TNFa receptor antibodies was required to obtain maximal inhibition of H202 release. The specificity of TNFa receptors in this pathway is indicated by the observation that antibodies against HLA-A,B,C, IL-8, and CD14, as well as IgC, had no significant effect on PMN functional responses. In addition, anti-TNFa receptor antibodies had no effect on PMN adhesion and spreading (data not shown), suggesting that the inhibition occurred at the level of transmembrane signaling. This is supported by data showing that anti-TNFa receptor antibodies failed to block H202 release stimulated by phorbol ester (Table I) Similar results have been obtained with other cells. Adding either anti-p55 or anti-p75 antibodies to human endothelial cells inhibited TNFa-stimulated IL-6 release by 41% and 42%, respectively, but the combination of both antibodies was required for more complete inhibition." Similarly, either p55 or p75 anti-TNFa receptor antibody partially blocked the binding of HL-60 cells to endothelial cell cultures, but a combination of both antibodies was required for complete inhibiti~n.'~ In another study, it was shown that tissue factor production by human umbilical vein endothelial cells requires both p55 and ~7 5 .~~ Finally. it was shown that induction of apoptosis in PC60 (rathouse T-cell hybridoma) cells requires both TNFa receptor^.^^ Thus, it appears that in many functional responses signaling through both TNFa receptors is required.
Several studies have shown that receptors for different ligands may also be functionally linked. For example, it was shown that activating PMN Fc receptors increased the association of CR3 (CDl Ib/CD18) with cortical microfilaments in PMN?4 suggesting that CR3 physically interacts with Fc receptors. These results confirm and extend previous studies showing that anti-Mac-1 (CDI lb) antibody inhibited IgG-stimulated PMN phagocyt~sis.~~ It was also reported that PMN chemotaxis to FMLP is inhibited by Fc fragments of IgG,25,26 suggesting that FcRIIl and FMLP receptors are also functionally associated. Our data show that antibodies against the p55 and p75 TNFa receptors inhibited H202 release stimulated by FMLP. These results, supporting the hypothesis that TNFa and FMLP receptors are functionally linked, perhaps through TNFa release, which mediates autocrine activation of adherent PMN. Future efforts will be directed toward determining the specific roles that p55 and p75 TNFa receptors play in FMLP activation of adherent PMN.
For
